Despite promising early observations [71], attempts to combine MEK inhibition with immune checkpoint inhibition for the treatment of mismatch-proficient CRC so far have yielded underwhelming results in phase 3 clinical testing [72]. Here, MAP2K7 is linked to colorectal carcinoma.